Baird raised the firm’s price target on HealthEquity to $97 from $92 and keeps an Outperform rating on the shares. The firm continues to recommend the stock to long-term growth investors and raised its price target on greater clarity on its three-year earnings growth trajectory.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HQY:
- HealthEquity Reports Year-End Sales Metrics
- HealthEquity price target raised to $93 from $85 at BofA
- HealthEquity Recognized by Glassdoor as a Top U.S. Workplace for 2024
- Wells says key metrics tracking ahead as HealthEquity provides sales outlook
- HealthEquity Announces Year-End HSA Sales Outlook; Presentation at J.P. Morgan Healthcare Conference; Investor Day
